Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

As of February 6, 2023, the average one-year price target for Axonics Modulation Technologies is $85.23. The forecasts range from a low of $65.65 to a high of $105.00. The average price target ...

As of January 31, 2023, the average one-year price target for Axonics Modulation Technologies is $85.23. The forecasts range from a low of $65.65 to a high of $105.00. The average price target ...

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating ...

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Tuesday reported a loss of $19.1 million in its first quarter. On a per-share basis, the Irvine, ...